JP2022507267A - 置換イソインドリノン - Google Patents

置換イソインドリノン Download PDF

Info

Publication number
JP2022507267A
JP2022507267A JP2021525755A JP2021525755A JP2022507267A JP 2022507267 A JP2022507267 A JP 2022507267A JP 2021525755 A JP2021525755 A JP 2021525755A JP 2021525755 A JP2021525755 A JP 2021525755A JP 2022507267 A JP2022507267 A JP 2022507267A
Authority
JP
Japan
Prior art keywords
compound
alkyl
cells
cancer
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507267A5 (enExample
Inventor
カイル ダブリュー．エイチ． チャン，
アパラジタ ホスコテ チョウラシア，
ポール イー． エルドマン，
リア ファン，
イメルダ ラム，
フランク メルキューリオ，
ロバート サリバン，
エドゥアルド トーレス，
Original Assignee
バイオセリックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオセリックス， インコーポレイテッド filed Critical バイオセリックス， インコーポレイテッド
Publication of JP2022507267A publication Critical patent/JP2022507267A/ja
Publication of JP2022507267A5 publication Critical patent/JP2022507267A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021525755A 2018-11-13 2019-11-12 置換イソインドリノン Pending JP2022507267A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862760813P 2018-11-13 2018-11-13
US62/760,813 2018-11-13
PCT/US2019/060920 WO2020102195A1 (en) 2018-11-13 2019-11-12 Substituted isoindolinones

Publications (2)

Publication Number Publication Date
JP2022507267A true JP2022507267A (ja) 2022-01-18
JP2022507267A5 JP2022507267A5 (enExample) 2022-11-21

Family

ID=68808545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525755A Pending JP2022507267A (ja) 2018-11-13 2019-11-12 置換イソインドリノン

Country Status (9)

Country Link
US (2) US10844039B2 (enExample)
EP (1) EP3880669A1 (enExample)
JP (1) JP2022507267A (enExample)
CN (1) CN113423701A (enExample)
AU (1) AU2019381688A1 (enExample)
CA (1) CA3119343C (enExample)
IL (1) IL283057A (enExample)
TW (1) TW202031641A (enExample)
WO (1) WO2020102195A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113423701A (zh) * 2018-11-13 2021-09-21 拜欧斯瑞克斯公司 取代的异吲哚啉酮
KR20220103753A (ko) 2019-11-19 2022-07-22 브리스톨-마이어스 스큅 컴퍼니 헬리오스 단백질의 억제제로서 유용한 화합물
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
AU2021402911A1 (en) 2020-12-14 2023-07-06 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
PT4320112T (pt) * 2021-04-06 2025-07-07 Bristol Myers Squibb Co Compostos de oxoisoindolina substituídos por piridinilo
US20240294500A1 (en) * 2021-06-08 2024-09-05 Hangzhou Glubio Pharmaceutical Co., Ltd. Isoindolinone compounds, and uses thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
EP4540241A1 (en) * 2022-06-16 2025-04-23 Monte Rosa Therapeutics AG Substituted piperidines as ck1a degraders
EP4631937A1 (en) * 2022-12-07 2025-10-15 Hangzhou Glubio Pharmaceutical Co., Ltd. Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
PL249026B1 (pl) * 2022-12-09 2026-02-23 Univ Mikolaja Kopernika W Toruniu Pochodna azetydyno-2,4-dionu, sposób jej otrzymywania i zastosowanie
CN120097964A (zh) * 2023-12-05 2025-06-06 珠海宇繁生物科技有限责任公司 一种ikzf1降解剂及其制备方法和应用
WO2025221826A1 (en) * 2024-04-17 2025-10-23 Bristol-Myers Squibb Company Compounds for the degradation of alk proteins

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506861A (ja) * 1998-03-16 2002-03-05 コルジーン コーポレイション ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
JP2004525889A (ja) * 2000-12-27 2004-08-26 セルジーン・コーポレーション イソインドール−イミド化合物、組成物、およびそれらの使用
JP2010502627A (ja) * 2006-08-30 2010-01-28 セルジーン・コーポレーション ５−置換イソインドリン化合物
WO2017176958A1 (en) * 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
JP2017533955A (ja) * 2014-10-30 2017-11-16 カンプー バイオファーマシューティカルズ リミテッド イソインドリン誘導体、その中間体、製造方法、薬物組成物及び応用
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017201069A1 (en) * 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
CN107739389A (zh) * 2017-11-03 2018-02-27 华东师范大学 3位取代的(1‑氧代异吲哚啉‑2‑基)哌啶‑2,6‑二酮类化合物及其合成方法
WO2018052949A1 (en) * 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
WO2018071606A1 (en) * 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP2018515545A (ja) * 2015-05-22 2018-06-14 バイオセリックス， インコーポレイテッド タンパク質を標的とする化合物、その組成物、方法、および使用
WO2019173224A1 (en) * 2018-03-05 2019-09-12 Biotheryx, Inc. Deuterated compounds and chimeras and uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02214856A (ja) 1989-02-16 1990-08-27 Konica Corp ハロゲン化銀カラー写真感光材料
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE69734290T2 (de) 1996-11-05 2006-07-06 The Children's Medical Center Corp., Boston Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
US6093737A (en) 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
JP2000159761A (ja) 1998-11-30 2000-06-13 Yoshio Takeuchi フルオロサリドマイド
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
ES2172474B1 (es) 2001-03-01 2004-01-16 Fundacion Universitaria San Pa Derivados de glutarimida como agentes terapeuticos.
NZ531294A (en) 2001-08-06 2005-11-25 Childrens Medical Center Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
TWI298724B (en) 2001-11-15 2008-07-11 Celgene Corp Pharmaceutically active isoindoline derivatives
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CN1164586C (zh) 2002-10-28 2004-09-01 中国科学院长春应用化学研究所 沙利度胺及其衍生物的制备方法
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
CH696542A5 (de) 2003-07-09 2007-07-31 Siegfried Ltd Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
CN100398534C (zh) 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
WO2005028436A2 (en) 2003-09-17 2005-03-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US7612096B2 (en) 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
MXPA06010699A (es) 2004-03-22 2006-12-15 Celgene Corp Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel.
JP2005336157A (ja) 2004-04-30 2005-12-08 Arigen Inc 光学活性サリドマイドおよびその誘導体の製造法
ES2437592T3 (es) 2004-09-03 2014-01-13 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
ZA200704784B (en) 2004-11-12 2008-10-29 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
KR20070108909A (ko) 2005-02-18 2007-11-13 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 알데스류킨과 함께 사용하는 항혈관형성제
CN100383139C (zh) 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
ES2434946T3 (es) * 2005-08-31 2013-12-18 Celgene Corporation Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
AU2006332680A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
US20080064876A1 (en) 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
JP2009001528A (ja) 2007-06-22 2009-01-08 Nagoya Institute Of Technology ５’−ヒドロキシサリドマイド誘導体及びその製造方法
US20090155207A1 (en) 2007-11-29 2009-06-18 Hariri Robert J Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders
US7964354B2 (en) 2007-12-20 2011-06-21 Celgene Corporation Use of micro-RNA as a biomarker of immunomodulatory drug activity
US20100098657A1 (en) 2007-12-27 2010-04-22 Schafer Peter H Method of Treating Cancer with Immunomodulatory Compounds and IgG
US20090171093A1 (en) 2007-12-28 2009-07-02 Yoshio Takeuchi 3'-Fluoro-5'-hydroxythalidomide and derivatives thereof
US20090232796A1 (en) 2008-02-20 2009-09-17 Corral Laura G Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
JP2009215195A (ja) 2008-03-10 2009-09-24 Nagoya Institute Of Technology ５’−フルオロサリドマイド誘導体及びその製造方法
JP5561577B2 (ja) 2009-07-01 2014-07-30 国立大学法人 名古屋工業大学 光学活性３’−フルオロサリドマイド誘導体の製造方法
US9217743B2 (en) 2009-10-20 2015-12-22 Tokyo Institute Of Technology Screening method utilizing thalidomide-targeting factor
ES2664872T3 (es) 2010-06-18 2018-04-23 Taiho Pharmaceutical Co., Ltd Moduladores PRPK-TPRKB y sus usos
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
WO2014180882A2 (en) 2013-05-07 2014-11-13 Universitat De Barcelona Treatment of brain metastasis from cancer
WO2015107196A1 (en) 2014-01-20 2015-07-23 Institut Curie Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US9931332B2 (en) 2014-07-30 2018-04-03 University Of Southern California Compositions and methods for treating primary effusion lymphoma
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016301196B2 (en) 2015-08-06 2022-09-08 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017117473A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional molescules for her3 degradation and methods of use
WO2017117474A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
CA3017740A1 (en) 2016-03-16 2017-09-21 Pearlie BURNETTE Small molecules against cereblon to enhance effector t cell function
JP7037500B2 (ja) 2016-04-06 2022-03-16 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｍｄｍ２タンパク質分解剤
US10696635B2 (en) 2016-04-18 2020-06-30 The Scripps Research Institute Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
EP3892272B1 (en) 2016-04-22 2024-07-24 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
AU2017254702B2 (en) 2016-04-22 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
JP6921114B2 (ja) 2016-04-22 2021-08-18 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ８（ｃｄｋ８）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ８の分解および使用法
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CA3025805A1 (en) 2016-06-23 2017-12-28 James Bradner Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use
CA3025806C (en) 2016-06-23 2023-04-04 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN110062759B (zh) 2016-09-13 2022-05-24 密执安大学评议会 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
CN107056772A (zh) 2017-01-23 2017-08-18 中国药科大学 基于cereblon配体诱导BET降解的双功能分子及其制备和应用
CN107698575A (zh) 2017-09-26 2018-02-16 中国药科大学 cereblon配体介导的新型BET蛋白降解的双功能分子及其制备和应用
CA3106239A1 (en) * 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
CN113423701A (zh) * 2018-11-13 2021-09-21 拜欧斯瑞克斯公司 取代的异吲哚啉酮
US20230045737A1 (en) 2018-12-05 2023-02-09 Vividion Therapeutics, Inc. Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506861A (ja) * 1998-03-16 2002-03-05 コルジーン コーポレイション ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
JP2004525889A (ja) * 2000-12-27 2004-08-26 セルジーン・コーポレーション イソインドール−イミド化合物、組成物、およびそれらの使用
JP2010502627A (ja) * 2006-08-30 2010-01-28 セルジーン・コーポレーション ５−置換イソインドリン化合物
JP2017533955A (ja) * 2014-10-30 2017-11-16 カンプー バイオファーマシューティカルズ リミテッド イソインドリン誘導体、その中間体、製造方法、薬物組成物及び応用
JP2018515545A (ja) * 2015-05-22 2018-06-14 バイオセリックス， インコーポレイテッド タンパク質を標的とする化合物、その組成物、方法、および使用
WO2017176958A1 (en) * 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017201069A1 (en) * 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
WO2018052949A1 (en) * 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
WO2018071606A1 (en) * 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN107739389A (zh) * 2017-11-03 2018-02-27 华东师范大学 3位取代的(1‑氧代异吲哚啉‑2‑基)哌啶‑2,6‑二酮类化合物及其合成方法
WO2019173224A1 (en) * 2018-03-05 2019-09-12 Biotheryx, Inc. Deuterated compounds and chimeras and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDER L. RUCHELMAN, HON-WAH MAN, WEIHONG ZHANG, ROGER CHEN, LORI CAPONE, JIAN KANG, ANASTASIA PA: "Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23(1), JPN6023044004, 27 October 2012 (2012-10-27), NL, pages 360 - 365, ISSN: 0005327320 *
SCOTT G. STEWART, DANIEL SPAGNOLO, MARTA E. POLOMSKA, MELVIN SIN, MAHDAD KARIMI AND LAWRENCE J. ABRA: "Synthesis and TNF expression inhibitory properties of new thalidomide analogues derived via Heck cro", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17(21), JPN6023044003, 25 August 2007 (2007-08-25), NL, pages 5819 - 5824, ISSN: 0005327321 *
VLAD BACAUANU, SEBASTIEN CARDINAL, MOTOSHI YAMAUCHI, MASARU KONDO, DAVID F. FERNANDEZ, RICHARD REMY,: "Metallaphotoredox Difluoromethylation of Aryl Bromides", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 57(21), JPN6023044002, 28 August 2018 (2018-08-28), DE, pages 12543 - 12548, ISSN: 0005183999 *

Also Published As

Publication number Publication date
CA3119343A1 (en) 2020-05-22
US20200325114A1 (en) 2020-10-15
WO2020102195A1 (en) 2020-05-22
TW202031641A (zh) 2020-09-01
US11352338B2 (en) 2022-06-07
AU2019381688A1 (en) 2021-06-03
US10844039B2 (en) 2020-11-24
IL283057A (en) 2021-06-30
US20200148663A1 (en) 2020-05-14
CA3119343C (en) 2024-01-16
EP3880669A1 (en) 2021-09-22
CN113423701A (zh) 2021-09-21

Similar Documents

Publication Publication Date Title
US11352338B2 (en) Substituted isoindolinones
US12559473B2 (en) Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
US11285218B2 (en) Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
US20210139500A1 (en) Compounds targeting proteins, compositions, methods, and uses thereof
JP6629885B2 (ja) タンパク質を標的とする化合物、その組成物、方法、および使用
TWI734715B (zh) 趨化因子受體調節劑
US11236103B2 (en) Bifunctional compounds
US11667663B2 (en) Cyclic dinucleotides as anticancer agents
US11427610B2 (en) Cyclic dinucleotides as anticancer agents
BR112020024351A2 (pt) moléculas de ligação contra bcma e usos das mesmas
US10584133B2 (en) Thienopyrimidinone compounds
JP2020532529A (ja) 抗癌剤としての環状ジヌクレオチド
US9458158B2 (en) Bicyclic heterocycle compounds and their uses in therapy
JP2020536897A (ja) 抗がん剤としての環状ジヌクレオチド
CN117098757A (zh) Gpr84拮抗剂和其用途
KR20240021227A (ko) 방사성면역접합체와 체크포인트 억제제의 조합 요법
TW202500139A (zh) 經取代之苯基㗁唑酮化合物
KR20260020409A (ko) Ikzf1-4 단백질의 수준을 감소시키기 위한 치환된 옥사졸론 화합물
US20250066369A1 (en) Bicyclic phthalazin-1(2h)-one derivatives and related uses
RU2829901C2 (ru) Триспецифические молекулы, связывающие bcma, и пути их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240521